Indication

Familial hyperkalemic periodic paralysis

Familial hyperkalemic periodic paralysis is a rare, autosomal dominant neuromuscular channelopathy that primarily affects skeletal muscle function in children and adults. Read more about Familial hyperkalemic periodic paralysis

5 drugs 5 manufacturers

Advertisement

Drugs that treat it

Common Familial hyperkalemic periodic paralysis therapies.

Showing 1–5 of 5 drugs

DICHLORPHENAMIDE

CARBONIC ANHYDRASE INHIBITORS·FAMILIAL HYPERKALEMIC PERIODIC PARALYSIS·+1
TORRENT PHARMAC

DICHLORPHENAMIDE

CARBONIC ANHYDRASE INHIBITORS·FAMILIAL HYPERKALEMIC PERIODIC PARALYSIS·+1
RISING PHARM
Filter & compare in the drug finder →Opens the drug finder with Familial hyperkalemic periodic paralysis preselected.

News & literature

Coming soon

Related codes

Coming soon
Coming soon

About Familial hyperkalemic periodic paralysis.

Familial hyperkalemic periodic paralysis is a rare, autosomal dominant neuromuscular channelopathy that primarily affects skeletal muscle function in children and adults.

It is classically caused by gain-of-function mutations in the *SCN4A* gene encoding the voltage-gated skeletal muscle sodium channel Nav1.4, which lead to impaired channel inactivation, sustained sarcolemmal depolarization, and temporary loss of muscle fiber excitability.

Clinically, the condition is defined by recurrent, transient episodes of flaccid muscle weakness or paralysis that are frequently accompanied by elevated serum potassium concentrations and subclinical or clinical myotonia.

Episodes typically involve the proximal limbs and are commonly triggered by rest following strenuous physical exertion, fasting, cold exposure, or potassium-rich dietary intake.

Personalize your experience

Follow Familial hyperkalemic periodic paralysis and get updates as they land.

Create a free account

Follow an indication and get alerts when its drugs, labels, or guidelines change

Save any drug on this page to your favorites, synced across devices

AI-curated peer-reviewed research, summarized for your specialty

A morning digest of indication-relevant updates, when you want it